GILEAD SCIENCES, INC. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0000882095
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2026 · 5 positions · Total reported value $1.46B · Top-10 concentration 100.0% · Updated 2026-11-06
Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR
Turnover: 0.0% · 0 new · 0 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q3 2026 13F filing, GILEAD SCIENCES, INC. disclosed 5 equity positions with a combined reported value of $1.46B. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / Buy & Hold.
The largest disclosed positions as of Q3 2026 were RCUS ($811.70M), LKFT ($501.28M), ASMB ($116.91M). By sector, the heaviest allocations are Health Care 65.8%, Other 34.2%. Versus the prior quarter, allocation shifted toward Other (+3.9pp) and away from Health Care (-3.9pp).
Versus the prior quarter, GILEAD SCIENCES, INC. opened 0 new positions, trimmed 0 and fully exited 0, a turnover rate of 0.0% of positions. The portfolio's overlap with the prior quarter was 100% of names.
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
Insider Transactions (Form 4)
Latest GILEAD SCIENCES, INC. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-05-26 | Award | ASSEMBLY BIOSCIENCES, INC. | 471,698 | $26.50 | SEC filing |
Fund Profile
Gilead Sciences files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 5 positions worth $1.65B in total. HoldingsHub carries 7 quarters of its filings (Q4 2024–Q2 2026).
Portfolio Structure
- 5 positions · $1.65B reported value (Q2 2026)
- Top 10 holdings = 100.0% of reported value
- Largest position: RCUS (ARCUS BIOSCIENCES INC) at 58.8%
- Average position size: $329.75M
Sector Tilt
- Health Care 69.7%
- (classified holdings cover 70% of value)
Quarterly Activity
- Q2 2026: 1 added, 1 exited
- 4 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
31.42M | $811.70M | 55.45% | Hold | |
| 2 |
|
16.71M | $501.28M | 34.24% | Hold | |
| 3 |
|
4.98M | $116.91M | 7.99% | Hold | |
| 4 |
|
4.13M | $28.06M | 1.92% | Hold | |
| 5 |
|
650.39K | $5.89M | 0.40% | Hold |
FAQ
What did GILEAD SCIENCES, INC. buy in 2026-Q3?
In its 2026-Q3 13F filing, GILEAD SCIENCES, INC. reported 5 equity positions worth $1.46B in aggregate; its largest disclosed positions were RCUS ($811.70M), LKFT ($501.28M), ASMB ($116.91M).
How large is GILEAD SCIENCES, INC.'s portfolio?
GILEAD SCIENCES, INC. reported $1.46B of long equity holdings across 5 positions as of 2026-Q3. Top-10 holdings account for 100.0% of reported value.
What is GILEAD SCIENCES, INC.'s investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / Buy & Hold, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.